MarketPR
Hundreds of consumers have filed lawsuits against Novo Nordisk and Eli Lilly, alleging that their GLP-1 receptor agonists increase the risk of nonarteritic anterior ischemic optic neuropathy, a rare condition that causes sudden vision loss.
The legal action targets the manufacturers of Ozempic, Wegovy, Mounjaro, and Zepbound, with plaintiffs claiming the drugs directly caused the optic nerve injury.
Both companies dispute the allegations, pointing to internal research and ongoing safety monitoring to refute the causal link.
The Operational Safety Review The core of the dispute centers on the physical mechanism of NAION, where blood flow to the optic nerve is abruptly reduced.
Keep reading